China Diabetes Devices Market Size
| Study Period | 2019-2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 7.43 Billion |
| Market Size (2029) | USD 9.33 Billion |
| CAGR (2024 - 2029) | 4.66 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
China Diabetes Devices Market Analysis
The China Diabetes Devices Market size is estimated at USD 7.43 billion in 2024, and is expected to reach USD 9.33 billion by 2029, growing at a CAGR of 4.66% during the forecast period (2024-2029).
China has witnessed a significant rise in the prevalence of diabetes in recent decades, posing a major public health challenge for the nation. This surge in diabetes cases can be primarily attributed to factors such as rapid urbanization, sedentary lifestyles, unhealthy dietary habits, and an aging population. According to data from the International Diabetes Federation (IDF), China has the highest number of adults diagnosed with diabetes worldwide, surpassing 100 million individuals.
As the diabetes epidemic continues to unfold, there has been a corresponding increase in the demand for diabetes devices. These devices play a crucial role in managing diabetes by equipping individuals with tools to monitor their blood glucose levels, administer insulin, and track their overall health. Glucose meters, insulin pumps, continuous glucose monitoring (CGM) systems, and insulin pens are among the commonly used devices in diabetes management.
The growing population of individuals with diabetes in China has stimulated innovation and investment in the diabetes devices market. Both domestic and international manufacturers are capitalizing on this escalating demand by introducing advanced technologies and expanding their range of products. Chinese companies are leveraging their expertise in manufacturing and research to develop cost-effective devices that cater to the specific needs of the local population.
Furthermore, the Chinese government has acknowledged the pressing need to tackle the diabetes crisis and has introduced a range of measures to enhance diabetes management and prevention. These initiatives involve raising public awareness, advocating for healthy lifestyles, improving healthcare access, and providing subsidies for diabetes devices to low-income individuals.
In conclusion, the expanding diabetes population in China is propelling the growth of the diabetes devices market, emphasizing innovation, affordability, and accessibility. Dealing with the diabetes epidemic necessitates a holistic approach that covers prevention, early detection, and effective management strategies. By investing in diabetes prevention and treatment, China can alleviate the disease's impact and enhance the health and well-being of its populace.
China Diabetes Devices Market Trends
Monitoring Devices Market is growing with the highest CAGR in forecast period
Patients diagnosed with type-1 diabetes (T1D) are tasked with maintaining a healthy lifestyle, a challenge influenced by individual personality traits, social interactions, socioeconomic circumstances, and environmental factors. The integration of continuous glucose monitoring (CGM) alongside multiple daily injections (MDI) has proven effective in reducing both non-severe and severe hypoglycemia among individuals with T1 diabetes prone to such events. Remarkably, even amidst the challenging conditions imposed by the severe lockdown during the COVID-19 pandemic crisis, patients at high risk of hypoglycemia managed to control their blood sugar levels through standalone continuous glucose monitoring.
Managing viral infections in individuals with diabetes poses challenges due to variations in blood glucose (BG) levels. Real-time continuous glucose monitoring (RT-CGM) enables the monitoring of BG trends, allowing for intervention to prevent drastic fluctuations before they lead to complications. The Dexcom G4 Platinum CGM system's impressive range of up to 6.0 meters reduces the need for medical personnel to enter isolation rooms, enhancing safety protocols.
These advancements contribute to the growth of the monitoring device market in China. The increasing number of generic manufacturers in the country aligns with the growing preference among type-1 diabetes patients for cost-effective treatments, thereby supporting the expansion of the market under scrutiny.
Increasing Type -1 Diabetes Population in China
According to estimates, 1 in 10 Chinese citizens have diabetes. During the 21st Century, millions of new cases of diabetes are occurring each year. However, a precise statistic for diabetes in China is difficult to calculate because many cases remain undetected. China is believed to have surpassed India as the country with the most significant diabetes population in the world.
Diabetes is most prevalent in China's cities, where economic growth is accelerating, and traditional dietary patterns are rapidly eroding. According to China health experts, the fundamental causes of this diabetes number spike include urbanization, improving living standards, and an aging population. According to the National Health Commission, China has made steps to reduce diabetic and high blood pressure patients' medical expenses by reimbursing outpatients for more than half of their medication costs (NHC).
According to the National Metabolic Disease Clinical Research Center, more hospitals in China will establish National Metabolic Management Centers (MMC) as part of their exploration of a new model of diabetes treatment. According to the National Health Commission, China Statistics, MMCs have provided services for more than 200,000 patients over the last two years.
As a result, the diabetes care market in China is predicted to expand gradually in the coming years.
China Diabetes Devices Industry Overview
The new technologies in diabetes devices, like continuous glucose monitoring, have increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead on its way in the race to create an artificial pancreas system rather than merely offering a boost to the continuous glucose monitoring device market.
China Diabetes Devices Market Leaders
-
Abbott
-
Medtronics
-
Roche
-
Becton, Dickinson & Company
-
Dexcom
*Disclaimer: Major Players sorted in no particular order
China Diabetes Devices Market News
- February 2023: The MiniMed670G BLE, developed by Medtronic MiniMed, has received approval from the China NMPA. This advanced product includes an insulin pump kit, transmitter kit, and glucose sensor. It incorporates two key technologies: a hybrid closed-loop algorithm for auto mode and electrochemical impedance spectroscopy technology to monitor sensor status, ensuring accurate glucose readings.
- June 2022: LifeScan revealed a significant development as the peer-reviewed journal Diabetes Technology and Therapeutics (DTT) published Real World Evidence showcasing improved glycemic control in individuals with diabetes. This positive outcome is attributed to the utilization of a Bluetooth-connected Blood Glucose Meter in conjunction with a Mobile Diabetes Management Application. The OneTouch Reveal mobile app, paired with the OneTouch Verio Reflect meter via Bluetooth wireless technology, emerges as a pivotal tool supporting enhanced glycemic control for those managing diabetes.
China Diabetes Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Dynamics
- 4.2.1 Market Drivers
- 4.2.2 Market Restraints
-
4.3 Industry Attractiveness - Porter's Five Forces Analysis
- 4.3.1 Bargaining Power of Suppliers
- 4.3.2 Bargaining Power of Consumers
- 4.3.3 Threat of New Entrants
- 4.3.4 Threat of Substitute Products and Services
- 4.3.5 Intensity of Competitive Rivalry
5. Market Segmentation
-
5.1 Monitoring Devices
- 5.1.1 Self-monitoring Blood Glucose Devices
- 5.1.1.1 Glucometer Devices
- 5.1.1.2 Test Strips
- 5.1.1.3 Lancets
- 5.1.2 Continuous Glucose Monitoring
- 5.1.2.1 Sensors
- 5.1.2.2 Receivers (Receivers and Transmitters)
-
5.2 Management Devices
- 5.2.1 Insulin Delivery Devices
- 5.2.1.1 Insulin Pump
- 5.2.1.1.1 Insulin Pump Device
- 5.2.1.1.2 Insulin Pump Reservoir
- 5.2.1.1.3 Infusion Set
- 5.2.1.2 Insulin Syringes
- 5.2.1.3 Insulin Disposable Pens
- 5.2.1.4 Insulin Cartridges in Reusable pens
- 5.2.1.5 Insulin Jet Injectors
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Roche
- 7.1.2 Abbott
- 7.1.3 Johnson & Johnson
- 7.1.4 Novo Nordisk
- 7.1.5 Becton, Dickinson & Company
- 7.1.6 Medtronic
- 7.1.7 SinoCare
- 7.1.8 Sanofi
- 7.1.9 ARKRAY Inc.
- 7.1.10 Ascensia Diabetes Care
- 7.1.11 ACON Laboratories Inc.
- 7.1.12 Eli Lilly
- 7.1.13 Bionime Corporation
- 7.1.14 Rossmax International Ltd.
- *List Not Exhaustive
- 7.2 COMPANY SHARE ANALYSIS
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
China Diabetes Devices Industry Segmentation
Utilizing continuous glucose monitoring (CGM), diabetes devices effectively track fluctuations in blood sugar levels and dynamically adjust insulin administration to prevent extremes of high or low blood glucose. While the introduction of automated insulin delivery systems (AIDs) has mitigated the psychological burden of managing diabetes, ongoing research aims to further enhance these technologies. Insulin doses are meticulously calculated by an insulin pen based on parameters prescribed by your healthcare provider. The China diabetes devices market is segmented into management devices and monitoring devices. The report offers the value (in USD) and volume (in units) for the above segments.
| Monitoring Devices | Self-monitoring Blood Glucose Devices | Glucometer Devices | |
| Test Strips | |||
| Lancets | |||
| Monitoring Devices | Continuous Glucose Monitoring | Sensors | |
| Receivers (Receivers and Transmitters) | |||
| Management Devices | Insulin Delivery Devices | Insulin Pump | Insulin Pump Device |
| Insulin Pump Reservoir | |||
| Infusion Set | |||
| Management Devices | Insulin Delivery Devices | Insulin Syringes | |
| Insulin Disposable Pens | |||
| Insulin Cartridges in Reusable pens | |||
| Insulin Jet Injectors |
China Diabetes Devices Market Research Faqs
How big is the China Diabetes Devices Market?
The China Diabetes Devices Market size is expected to reach USD 7.43 billion in 2024 and grow at a CAGR of 4.66% to reach USD 9.33 billion by 2029.
What is the current China Diabetes Devices Market size?
In 2024, the China Diabetes Devices Market size is expected to reach USD 7.43 billion.
Who are the key players in China Diabetes Devices Market?
Abbott, Medtronics, Roche, Becton, Dickinson & Company and Dexcom are the major companies operating in the China Diabetes Devices Market.
What years does this China Diabetes Devices Market cover, and what was the market size in 2023?
In 2023, the China Diabetes Devices Market size was estimated at USD 7.08 billion. The report covers the China Diabetes Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the China Diabetes Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
China Diabetes Devices Industry Report
Statistics for the 2024 China Diabetes Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. China Diabetes Devices analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
